Navigating PD-1/PD-L1 Agents: Influential Factors in Choosing the Right Therapy

Author(s):

Félix Guerrero-Ramos, MD, PhD, FEBU ,Srikala Sridhar, MD

Key Takeaways

Route of administration impacts patient compliance and convenience, influencing the choice of PD-1/PD-L1 agents.
Duration of therapy affects patients' quality of life and is a key consideration in treatment selection.
Safety and efficacy profiles are critical in determining the most suitable PD-1/PD-L1 agent.
Place of administration, such as outpatient versus inpatient settings, influences logistical considerations.
Drug preservation, biomarker availability, and cost are significant factors in the decision-making process.

Panelists discuss how various factors, such as route of administration, duration of therapy, safety, efficacy, and cost, could influence the selection of different PD-1/PD-L1 agents once they receive approval, highlighting the importance of these considerations in optimizing patient care.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP: 1.Exploring NMIBC: Overview, Symptoms, Risk Factors and Staging

EP: 2.NMIBC Treatment Insights: Standard of Care, BCG Immune Response, and Patient Outcomes

EP: 3.Exploring PD-1/PD-L1 Pathways and Innovative Treatments for NMIBC

EP: 4.Innovations in NMIBC Treatment: The Synergy of BCG and PD-1/PD-L1 Inhibitors

EP: 5.Collaborative Strategies: Urologists and Oncologists Enhancing Outcomes for High-Risk NMIBC

Now Viewing

EP: 6.Navigating PD-1/PD-L1 Agents: Influential Factors in Choosing the Right Therapy

EP: 7.Phase 3 Trials of PD-1/PD-L1 Inhibitors in NMIBC

EP: 8.Examining the Effects of PD-1/PD-L1 Inhibitor Differences on Patient Outcomes: Adherence, BCG Maintenance, and Resource Management

EP: 9.Exploring Emerging Data in NMIBC

EP: 10.Optimizing Multidisciplinary Care for BCG-Naive, High-Risk NMIBC

Video content above is prompted by the following:

What factors could influence the choice between different PD-1/PD-L1 agents if they are eventually approved [ie, route of administration, duration of therapy, safety, efficacy, place of administration, drug preservation, biomarkers, cost, etc]?

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!

Related Videos

Optimizing Multidisciplinary Care for BCG-Naive, High-Risk NMIBC

Exploring Emerging Data in NMIBC

Examining the Effects of PD-1/PD-L1 Inhibitor Differences on Patient Outcomes: Adherence, BCG Maintenance, and Resource Management

Phase 3 Trials of PD-1/PD-L1 Inhibitors in NMIBC

Collaborative Strategies: Urologists and Oncologists Enhancing Outcomes for High-Risk NMIBC

Innovations in NMIBC Treatment: The Synergy of BCG and PD-1/PD-L1 Inhibitors

Exploring PD-1/PD-L1 Pathways and Innovative Treatments for NMIBC

NMIBC Treatment Insights: Standard of Care, BCG Immune Response, and Patient Outcomes

Exploring NMIBC: Overview, Symptoms, Risk Factors and Staging